US adviser on board of firm that sold anthrax drug

(AP)—Former Navy Secretary Richard J. Danzig, who has served as a bio-warfare adviser to the president, the Pentagon, and the Department of Homeland Security, urged the government to stockpile an anti-anthrax drug while serving as a director for the company that supplied it, according to a report published Sunday.

While there is no evidence any nation or terrorist group has achieved it, Danzig warned for a decade that terrorists could easily engineer a strain of anthrax resistant to common antibiotics that could be a devastating threat to national security, according to an investigation by the (http://lat.ms/12K6Rxh ).

Danzig successfully suggested stockpiling a drug known as raxibacumab, or "raxi," to guard against the potential threat, and biotech startup Human Genome Sciences Inc. has won $334 million in federal contracts since 2006 to supply the drug that now goes for $5,100 a dose.

At the same time, Danzig was a director for the company, earning more than $1 million in company compensation between 2001 and 2012. It was the first product the company sold and the U.S. government remains the only buyer. The Rockville, Maryland-based company was acquired by in August for $3.6 billion.

Several officials who attended seminars led by Danzig said they had no knowledge of his ties to Human Genome Sciences.

"Holy smoke—that was a horrible conflict of interest," said Dr. Philip K. Russell, a physician, retired major-general and biodefense official in the George W. .

Federal law bars U.S. officials, including advisers and consultants, from giving counsel on matters in which they have a financial interest.

Danzig said there was no , and that he sought only to inform officials of the danger, not to lobby for the purchase of raxibacumab.

"My view was I'm not going to get involved in selling that," Danzig told the Times in an interview. "But at the same time now, should I not say what I think is right in the government circles with regard to this?"

Danzig added, "I feel that I've acted very properly with regard to this."

Danzig, 68, who served as Navy secretary in the Clinton administration and has since worked as a consultant, began warning about antibiotic-resistant anthrax in the wake of five deaths from anthrax-laced letters that came soon after the terrorist attacks of Sept. 11, 2001.

The in the letters was not resistant to antibiotics, but Danzig was soon warning of the possibility of a deadlier form of the germ, saying his interest in the subject came from "people whose technical skills exceed mine."

The Times investigation found seven papers Danzig had written on bioterrorism since 2001, and in only one did he disclose his ties to Sciences.

5 /5 (1 vote)
add to favorites email to friend print save as pdf

Related Stories

Rare anthrax case diagnosed in Minnesota

Aug 10, 2011

Minnesota health officials said Tuesday they are investigating a rare case of anthrax inhalation linked to exposure to the dreaded bacteria in the natural environment.

Recommended for you

Express Scripts turns to AbbVie in huge hepatitis C deal

3 hours ago

The nation's largest pharmacy benefits manager is throwing its weight into a fight over the high cost of treating hepatitis C, saying it will cover a drug from AbbVie while pulling back on those from rival drugmakers.

FDA OKs Cubist antibiotic for serious infections

Dec 20, 2014

The Food and Drug Administration has approved a new medicine to fight complex infections in the abdomen and urinary tract, the fourth antibiotic the agency has approved since May.

Xtoro approved for swimmer's ear

Dec 18, 2014

(HealthDay)—Xtoro (finafloxacin otic suspension) eardrops have been approved by the U.S. Food and Drug Administration to treat swimmer's ear, clinically known as acute otitis externa.

Drug interaction identified for ondansetron, tramadol

Dec 18, 2014

(HealthDay)—In the early postoperative period, ondansetron is associated with increased requirements for tramadol consumption, according to a review and meta-analysis published online Dec. 10 in Anaesthesia.

New system targets germs in donated blood plasma

Dec 17, 2014

(HealthDay)—A new system designed to eliminate germs in donated blood plasma and reduce the risk of transmitting a plasma-borne infection has been approved by the U.S. Food and Drug Administration.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.